AbCellera Biologics Inc. discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. Co.'s engine integrates technology, data science, infrastructure, and interdisciplinary teams to solve the antibody discovery problems. Co. has developed technology platforms to unlock drug classes, targets, and modalities, including transmembrane proteins, T-cell engagers, and peptide-MHCs. Co. is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two preclinical programs in its internal pipeline are ABCL575 and ABCL635. The ABCL average annual return since 2020 is shown above.
The Average Annual Return on the ABCL average annual return since 2020 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether ABCL average annual return since 2020 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ABCL average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|